Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood

Jung K, Laube C, Lein M, Lichtinghagen R, Tschesche H, Schnorr D, Loening SA (1998)
CLINICAL CHEMISTRY 44(5): 1060-1062.

Download
No fulltext has been uploaded. References only!
Journal Article | | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ;
Publishing Year
ISSN
PUB-ID

Cite this

Jung K, Laube C, Lein M, et al. Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY. 1998;44(5):1060-1062.
Jung, K., Laube, C., Lein, M., Lichtinghagen, R., Tschesche, H., Schnorr, D., & Loening, S. A. (1998). Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY, 44(5), 1060-1062.
Jung, K., Laube, C., Lein, M., Lichtinghagen, R., Tschesche, H., Schnorr, D., and Loening, S. A. (1998). Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY 44, 1060-1062.
Jung, K., et al., 1998. Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY, 44(5), p 1060-1062.
K. Jung, et al., “Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood”, CLINICAL CHEMISTRY, vol. 44, 1998, pp. 1060-1062.
Jung, K., Laube, C., Lein, M., Lichtinghagen, R., Tschesche, H., Schnorr, D., Loening, S.A.: Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. CLINICAL CHEMISTRY. 44, 1060-1062 (1998).
Jung, K, Laube, C, Lein, M, Lichtinghagen, R, Tschesche, Harald, Schnorr, D, and Loening, SA. “Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood”. CLINICAL CHEMISTRY 44.5 (1998): 1060-1062.
This data publication is cited in the following publications:
This publication cites the following data publications:

49 Citations in Europe PMC

Data provided by Europe PubMed Central.

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in multiple sclerosis.
Gerlach RF, Tanus-Santos JE., Clin Neurol Neurosurg 108(6), 2006
PMID: 16413675
Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196.
Zucker S, Wang M, Sparano JA, Gradishar WJ, Ingle JN, Davidson NE, Eastern Cooperative Oncology Group., Clin Breast Cancer 6(6), 2006
PMID: 16595036
Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation.
Rouy D, Ernens I, Jeanty C, Wagner DR., Anal Biochem 338(2), 2005
PMID: 15745750
Preanalytical conditions and circulating matrix metalloproteinases.
Verspaget HW, Kuyvenhoven JP, van Hoek B., Transplantation 79(6), 2005
PMID: 15785393
Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.
Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, Brieger D., Intern Med J 35(6), 2005
PMID: 15892761
Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma.
Makowski GS, Ramsby ML., Anal Biochem 322(2), 2003
PMID: 14596841
Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C.
Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R., Clin Chim Acta 316(1-2), 2002
PMID: 11750276
Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood.
Alby C, Ben Abdesselam O, Foglietti MJ, Beaudeux JL., Clin Chim Acta 325(1-2), 2002
PMID: 12367785
Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis.
Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A, Higashikata T, Inazu A, Koizumi J, Takegoshi T, Mabuchi H., Clin Chem Lab Med 39(5), 2001
PMID: 11434385
Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
Lein M, Jung K, Laube C, Hübner T, Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D, Loening SA., Int J Cancer 85(6), 2000
PMID: 10709099
MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate.
Hanemaaijer R, Sier CF, Visser H, Scholte L, van Lent N, Toet K, Hoekman K, Verheijen JH., Ann N Y Acad Sci 878(), 1999
PMID: 10415726
Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer.
Jung K, Laube C, Lein M, Türk I, Lichtinghagen R, Rudolph B, Schnorr D, Loening SA., Int J Cancer 78(3), 1998
PMID: 9766579

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 9590387
PubMed | Europe PMC

Search this title in

Google Scholar